OLIPASS CORPORATION — Investor Relations & Filings
Filings indexed
498
across all filing types
Latest filing
2026-05-12
Legal Proceedings Report
Country
KR
South Korea
Listing
KO
244460
OLIPASS CORPORATION is a research and development company focused on creating RNA therapeutics. The company's core activities are centered on its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. OPNA is a novel technology derived from Peptide Nucleic Acid (PNA) by introducing a cationic lipid moiety onto the nucleobase. This structural modification is designed to markedly improve cell permeability, a key challenge in nucleic acid-based drug delivery. The platform is optimized to induce exon skipping by specifically binding to target pre-mRNA inside the cell nucleus, enabling the discovery and development of new therapeutic candidates.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 기타경영사항(자율공시) | 2026-05-12 | Korean | |
| 주요사항보고서(회생절차개시신청) | 2026-05-07 | Korean | |
| 기타시장안내 (회생절차 개시신청 관련 시장안내) | 2026-05-07 | Korean | |
| [기재정정]투자판단관련주요경영사항 (OliPass PNA 플랫폼 기술 기반 희귀질환 치료제 및 면역항암제 관련 치료제 개발을 위한 Vanda 제약과 신약 공동연구개발 계약 체결) | 2026-04-30 | Korean | |
| [기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령) | 2026-04-30 | Korean | |
| [기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령) | 2026-04-30 | Korean |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45195705 | 기타경영사항(자율공시) | 2026-05-12 | Korean | ||
| 42619619 | 주요사항보고서(회생절차개시신청) | 2026-05-07 | Korean | ||
| 42619588 | 기타시장안내 (회생절차 개시신청 관련 시장안내) | 2026-05-07 | Korean | ||
| 39045558 | [기재정정]투자판단관련주요경영사항 (OliPass PNA 플랫폼 기술 기반 희귀질환 치료제 및 면역항암제 관련 치료제 개발을 위한 Vanda 제약과 신약 공동연구개발 계약 체결) | 2026-04-30 | Korean | ||
| 39045553 | [기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령) | 2026-04-30 | Korean | ||
| 39045545 | [기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령) | 2026-04-30 | Korean | ||
| 39045536 | [기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령) | 2026-04-30 | Korean | ||
| 33669254 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-04-07 | Korean | ||
| 33120351 | [기재정정]정기주주총회결과 | 2026-03-31 | Korean | ||
| 33120341 | [기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고 | 2026-03-31 | Korean | ||
| 33084964 | 사외이사의선임ㆍ해임또는중도퇴임에관한신고 | 2026-03-30 | Korean | ||
| 33084316 | 정기주주총회결과 | 2026-03-30 | Korean | ||
| 33047662 | [기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령) | 2026-03-26 | Korean | ||
| 33047661 | [기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령) | 2026-03-26 | Korean | ||
| 33047660 | [기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령) | 2026-03-26 | Korean | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
OLIPASS CORPORATION via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/17661/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=17661 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=17661 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=17661 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 17661}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for OLIPASS CORPORATION (id: 17661)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.